DaVita Guides FY Adj EPS to $14.10-$15.20, Above Consensus
DVA has more than doubled off its 52-week low of $101 on elevated volume (2.8× avg).
Summary
DaVita issued full-year adjusted EPS guidance of $14.10 to $15.20, a range that sits above the current consensus estimate of $13.80. The outlook reflects confidence in continued operational momentum following a strong Q1 that saw raised guidance and heavy buybacks. The midpoint of $14.65 implies roughly 15% growth over the prior year, driven by volume gains and cost discipline in its core dialysis business. This follows the $500 million term loan refinancing in June, which improved the balance sheet. The stock has already rallied 22% year-to-date, so the bar for positive surprise was high — this guidance clears it.
At the time of this announcement, DVA was trading at $218.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $14.6B. The 52-week trading range was $101.00 to $247.49. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.